Drug Profile
Research programme: Alzheimer's disease therapeutics - reMYND
Alternative Names: ReS10-T; ReS8-TLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator reMYND
- Class Antidementias; Small molecules
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Belgium
- 21 Jul 2016 Preclinical trials in Alzheimer's disease in Belgium (unspecified route)